ADC3680
As of the edition of 20 October 2026, ADC3680 is a drug: went quiet in 2014; acts on PTGDR2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2014
- Kind
- Unknown
- Registered trials
- 3, 0 stopped early
- Disease areas
- Lungs and airways; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of ADC3680.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PTGDR2 | Prostaglandin D2 receptor 2 | Q9Y5Y4 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 2 | 2 | 0 | 0 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Pulmagen Therapeutics | Lead sponsor of trials | 2010 to now |